Wedbush Has Pessimistic View of Nuvation Bio Q3 Earnings

Nuvation Bio Inc. (NYSE:NUVB) – Analysts at Wedbush dropped their Q3 2025 EPS estimates for Nuvation Bio in a research report issued on Monday, March 3rd. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.17) per share for the quarter, down from their previous forecast of ($0.16). Wedbush currently has a “Outperform” rating and a $5.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.73) EPS and FY2027 earnings at ($0.48) EPS.

A number of other analysts also recently commented on NUVB. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective (up previously from $6.00) on shares of Nuvation Bio in a report on Tuesday, January 7th. HC Wainwright lifted their target price on shares of Nuvation Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $8.20.

Nuvation Bio Stock Up 3.6 %

Shares of NYSE:NUVB opened at $1.89 on Thursday. The company has a market cap of $634.43 million, a price-to-earnings ratio of -0.87 and a beta of 1.47. The firm’s 50-day simple moving average is $2.44 and its 200-day simple moving average is $2.60. Nuvation Bio has a fifty-two week low of $1.67 and a fifty-two week high of $4.16.

Hedge Funds Weigh In On Nuvation Bio

A number of institutional investors have recently modified their holdings of the company. Forum Financial Management LP acquired a new position in shares of Nuvation Bio in the fourth quarter valued at approximately $29,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Nuvation Bio by 54.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 347,806 shares of the company’s stock valued at $925,000 after purchasing an additional 122,187 shares during the period. Wexford Capital LP grew its holdings in Nuvation Bio by 45.2% in the fourth quarter. Wexford Capital LP now owns 946,219 shares of the company’s stock valued at $2,517,000 after purchasing an additional 294,452 shares during the period. Two Sigma Investments LP grew its holdings in Nuvation Bio by 0.5% in the fourth quarter. Two Sigma Investments LP now owns 1,151,256 shares of the company’s stock valued at $3,062,000 after purchasing an additional 5,925 shares during the period. Finally, ProShare Advisors LLC grew its holdings in Nuvation Bio by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 51,060 shares of the company’s stock valued at $136,000 after purchasing an additional 16,801 shares during the period. Institutional investors and hedge funds own 61.67% of the company’s stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.